



August 28, 2025

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, Vice President
COO and CFO
Ryosuke Matsui
(TEL. 03-6214-3600)

Notice Regarding Appointment of Executive Officer

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. announces that, at the Board of Directors meeting held on August 28, 2025, it resolved to appoint an Executive Officer as outlined below.

1. Appointment of Executive Officer (Effective August 28, 2025)

Name	Title and Responsibilities
Takuya Kaneko	Executive Officer, CSO (Chief Strategy Officer)

2. Background of Appointment

The Group is working to establish a global management structure as it strives to make the leap toward becoming a global healthcare company, aiming for sustainable growth while maximizing shareholder value. As part of this process, we believe it is essential to diversify our revenue sources and build an optimal global business portfolio.

Mr. Kaneko has long been engaged in investment banking, where he has an extensive track record of supporting numerous M&A and financing transactions, including in the healthcare sector. He also has management experience at a medical start-up company. With his background in both finance and biotechnology, his participation will enable the Group to expand its revenue base in Japan through M&A and other initiatives, while advancing strategies to achieve its goal of becoming a global healthcare company.

3. Biography of Takuya Kaneko

April 1998	Joined Export-Import Bank of Japan (currently Japan Bank for International Cooperation)
August 2006	Joined Morgan Stanley Japan Securities Co., Ltd. (currently Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.)
April 2017	Executive Director, Investment Banking Division, Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.
November 2022	Joined Cellusion Inc. as CFO
February 2025	Appointed CEO, Cellusion Inc.
August 2025	Joined the Company as Executive Officer, CSO (Chief Strategy Officer)

4. Comment from Executive Officer CSO, Takuya Kaneko

" During my career in investment banking, I supported GNI Group's growth strategy. Several years have passed since then, and I have witnessed the Company steadily advance its global business while significantly expanding its revenue scale, making it a truly unique player among emerging pharmaceutical companies. I strongly believe that the Company has the potential to reach the next stage of growth, and I have decided to take this opportunity to participate in and help drive the Group's strategy. I am committed to supporting the Company's growth both in Japan and globally, and to contributing to the stakeholders of GNI Group as well as to the advancement of the healthcare industry."